课题基金 / 基金详情

Production of Alternate Adenovector Filovirus Vaccines

Production of Alternate Adenovector Filovirus Vaccines
替代腺载体丝状病毒疫苗的生产
批准号：
8946608
负责人：
Richard Schwartz
金额：
$216.61万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8946608
关键词：
Adenovirus VectorAdenovirusesAntibodiesClinicClinical TrialsCyclic GMPFilovirusHigh PrevalenceHumanImmune responseInfectionLaboratoriesLaboratory StudyNational Institute of Allergy and Infectious DiseasePan GenusPopulationProductionSerotypingVaccine Clinical TrialVaccine ProductionVaccinesVertebral columnbasedesignimmunogenicnovelpreclinical studyprogramsvectorvector vaccine

项目摘要

项目成果

Richard Schwartz的其他基金

相似基金

相关文献

中文摘要
翻译
本项目旨在制备GMP质量研究性替代丝状病毒腺载体疫苗，该疫苗基于血清5型腺病毒（包括非人（黑猩猩Ad3血清型））以外的腺载体骨架。VRC正在进行多组分埃博拉腺病毒载体疫苗的临床前和实验室研究。假设该疫苗对人类给药是安全的，并引发对丝状病毒感染的免疫应答。正在使用新的腺病毒骨架开发这些载体，使得疫苗可能在具有高流行率的Ad5抗体的群体中证明更具免疫原性。
英文摘要
This project is designed to prepare GMP quality investigational alternative Filovirus adenovector vaccines based on adenovector backbones other than serotype 5 adenovirus (including non-human (chimpanzee Ad3 serotype). VRC has ongoing preclinical and laboratory studies of multicomponent Ebola adenoviral vector vaccines. The hypothesis is that the vaccine will be safe for human administration and elicit immune responses to Filovirus infections. These vectors are being developed using novel adenovirus backbones so that the vaccines may protentially prove more immunogenic in populations that have a high prevalence of Ad5 antibody.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Production of a Broadly Neutralizing HIV Antibody (VRC01)
Development/Production-Alternative Serotype HIV Recombinant Adenoviral Vaccine
Development and Production of alphavirus vaccines
Development of a recombinant trimeric RSV-F vaccine (DS-Cav1)
海外基金